These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 24217611)
1. Angiogenesis inhibitors in the treatment of prostate cancer. Adesunloye BA; Karzai FH; Dahut WL Chem Immunol Allergy; 2014; 99():197-215. PubMed ID: 24217611 [TBL] [Abstract][Full Text] [Related]
2. Angiogenesis of prostate cancer and antiangiogenic therapy. Uehara H J Med Invest; 2003 Aug; 50(3-4):146-53. PubMed ID: 13678383 [TBL] [Abstract][Full Text] [Related]
3. From bevacizumab to tasquinimod: angiogenesis as a therapeutic target in prostate cancer. Schweizer MT; Carducci MA Cancer J; 2013; 19(1):99-106. PubMed ID: 23337763 [TBL] [Abstract][Full Text] [Related]
4. Classical and non-classical proangiogenic factors as a target of antiangiogenic therapy in tumor microenvironment. Marech I; Leporini C; Ammendola M; Porcelli M; Gadaleta CD; Russo E; De Sarro G; Ranieri G Cancer Lett; 2016 Sep; 380(1):216-26. PubMed ID: 26238184 [TBL] [Abstract][Full Text] [Related]
5. Angiogenesis and anti-angiogenic therapy in prostate cancer. Mukherji D; Temraz S; Wehbe D; Shamseddine A Crit Rev Oncol Hematol; 2013 Aug; 87(2):122-31. PubMed ID: 23375349 [TBL] [Abstract][Full Text] [Related]
6. Angiogenesis as a strategic target for prostate cancer therapy. Li Y; Cozzi PJ Med Res Rev; 2010 Jan; 30(1):23-66. PubMed ID: 19536866 [TBL] [Abstract][Full Text] [Related]
7. Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale. Ryan CJ; Lin AM; Small EJ Urol Oncol; 2006; 24(3):250-3. PubMed ID: 16678059 [TBL] [Abstract][Full Text] [Related]
8. Antiangiogenesis: a possible treatment option for prostate cancer? Longoria RL; Cox MC; Figg WD Clin Genitourin Cancer; 2005 Dec; 4(3):197-202. PubMed ID: 16425989 [TBL] [Abstract][Full Text] [Related]
9. Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate. Colombel M; Filleur S; Fournier P; Merle C; Guglielmi J; Courtin A; Degeorges A; Serre CM; Bouvier R; Clézardin P; Cabon F Cancer Res; 2005 Jan; 65(1):300-8. PubMed ID: 15665307 [TBL] [Abstract][Full Text] [Related]
10. The role of angiogenesis inhibitors in prostate cancer. Aragon-Ching JB; Dahut WL Cancer J; 2008; 14(1):20-5. PubMed ID: 18303479 [TBL] [Abstract][Full Text] [Related]
11. Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance. Cao Y; Zhong W; Sun Y Semin Cancer Biol; 2009 Oct; 19(5):338-43. PubMed ID: 19481151 [TBL] [Abstract][Full Text] [Related]
15. Drug development in prostate cancer. Ripple GH; Wilding G Semin Oncol; 1999 Apr; 26(2):217-26. PubMed ID: 10597732 [TBL] [Abstract][Full Text] [Related]
16. Castration-refractory prostate cancer: New drugs in the pipeline. Schrijvers D; Van Erps P; Cortvriend J Adv Ther; 2010 May; 27(5):285-96. PubMed ID: 20532721 [TBL] [Abstract][Full Text] [Related]
17. Angiogenesis inhibitors in prostate cancer therapy. Yu EM; Jain M; Aragon-Ching JB Discov Med; 2010 Dec; 10(55):521-30. PubMed ID: 21189223 [TBL] [Abstract][Full Text] [Related]
18. Breast tumour angiogenesis. Fox SB; Generali DG; Harris AL Breast Cancer Res; 2007; 9(6):216. PubMed ID: 18190723 [TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for prostate cancer - recent progress in clinical trials. Kipp RT; McNeel DG Clin Adv Hematol Oncol; 2007 Jun; 5(6):465-74, 477-9. PubMed ID: 17679921 [TBL] [Abstract][Full Text] [Related]
20. Novel antivascular efficacy of metronomic docetaxel therapy in prostate cancer: hnRNP K as a player. Benelli R; Monteghirfo S; Balbi C; Barboro P; Ferrari N Int J Cancer; 2009 Jun; 124(12):2989-96. PubMed ID: 19319982 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]